{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T10:56:16Z","timestamp":1772535376824,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"DOI":"10.7759\/cureus.104592","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:40:44Z","timestamp":1772527244000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Treatment With Rituximab for Severe Immune Thrombocytopenic Purpura During Hemodialysis"],"prefix":"10.7759","author":[{"given":"Mayuko","family":"Hanyuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiho","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Uchitsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayumi","family":"Kawamura,","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Sakurabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shokichi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper N","year":"2019","unstructured":"Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019, 381:945-55. 10.1056\/NEJMcp1810479","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert C","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al.. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019, 3:3829-66. 10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database","volume":"145","author":"Schoonen WM","year":"2009","unstructured":"Schoonen WM, Kucera G, Coalson J, et al.. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009, 145:235-44. 10.1111\/j.1365-2141.2009.07615.x","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf M","year":"2014","unstructured":"Khellaf M, Charles-Nelson A, Fain O, et al.. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014, 124:3228-36. 10.1182\/blood-2014-06-582346","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1887-9","article-title":"Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy","volume":"102","author":"Miyakawa Y","year":"2015","unstructured":"Miyakawa Y, Katsutani S, Yano T, et al.. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy. Int J Hematol. 2015, 102:654-61. 10.1007\/s12185-015-1887-9","journal-title":"Int J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.66.473","article-title":"Novel second-line treatments for immune thrombocytopenia [Article in Japanese]","volume":"66","author":"Kato H","year":"2025","unstructured":"Kato H. Novel second-line treatments for immune thrombocytopenia [Article in Japanese]. Rinsho Ketsueki. 2025, 66:473-80. 10.11406\/rinketsu.66.473","journal-title":"Rinsho Ketsueki"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042163","article-title":"Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options","volume":"25","author":"Mititelu A","year":"2024","unstructured":"Mititelu A, Onis\u00e2i MC, Ro\u0219ca A, Vl\u0103d\u0103reanu AM. Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options. Int J Mol Sci. 2024, 25:10.3390\/ijms25042163","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1411910","article-title":"CLINICAL PRACTICE. Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher A","year":"2015","unstructured":"Greinacher A. CLINICAL PRACTICE. Heparin-induced thrombocytopenia. N Engl J Med. 2015, 373:252-61. 10.1056\/NEJMcp1411910","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000044821","article-title":"Type II heparin-induced thrombocytopenia in a maintenance hemodialysis patient: a case report and literature review","volume":"104","author":"Zhang X","year":"2025","unstructured":"Zhang X, Zhou M, Wu P, Chen Y, Yan J. Type II heparin-induced thrombocytopenia in a maintenance hemodialysis patient: a case report and literature review. Medicine (Baltimore). 2025, 104:e44821. 10.1097\/MD.0000000000044821","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S496127","article-title":"COVID-19-associated immune thrombocytopenic purpura in a hemodialysis patient","volume":"15","author":"Mei S","year":"2024","unstructured":"Mei S, Xue C, Zhang Z, et al.. COVID-19-associated immune thrombocytopenic purpura in a hemodialysis patient. J Blood Med. 2024, 15:495-500. 10.2147\/JBM.S496127","journal-title":"J Blood Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4009\/jsdt.50.635","article-title":"A treatment option for idiopathic thrombocytopenic purpura in hemodialysis patients","volume":"50","author":"Inoue D","year":"2017","unstructured":"Inoue D, Usui R, Kumon S, NItta T, Danazol N. A treatment option for idiopathic thrombocytopenic purpura in hemodialysis patients. J Japanese Soc Dial Ther. 2017, 50:635-40. 10.4009\/jsdt.50.635","journal-title":"J Japanese Soc Dial Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.02.007","article-title":"Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus","volume":"10","author":"Lee SY","year":"2010","unstructured":"Lee SY, Hsu PY, Juan KC, Chang H, Huang WH, Lai PC. Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus. Int Immunopharmacol. 2010, 10:632-4. 10.1016\/j.intimp.2010.02.007","journal-title":"Int Immunopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151478","article-title":"Bleeding risk in hemodialysis patients","volume":"43","author":"van Eck van der Sluijs A","year":"2023","unstructured":"van Eck van der Sluijs A, Pai P, Zhu W, Ocak G. Bleeding risk in hemodialysis patients. Semin Nephrol. 2023, 43:151478. 10.1016\/j.semnephrol.2023.151478","journal-title":"Semin Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-020-01757-1","article-title":"The risk of bleeding for antiplatelet agents in haemodialysis patients: a meta-analysis","volume":"21","author":"Wang Q","year":"2020","unstructured":"Wang Q, Xie X, Xu G. The risk of bleeding for antiplatelet agents in haemodialysis patients: a meta-analysis. BMC Nephrol. 2020, 21:106. 10.1186\/s12882-020-01757-1","journal-title":"BMC Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert C","year":"2011","unstructured":"Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011, 117:4190-207. 10.1182\/blood-2010-08-302984","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold DM","year":"2007","unstructured":"Arnold DM, Dentali F, Crowther MA, et al.. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007, 146:25-33. 10.7326\/0003-4819-146-1-200701020-00006","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh S","year":"2015","unstructured":"Chugh S, Darvish-Kazem S, Lim W, et al.. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015, 2:75-81. 10.1016\/s2352-3026(15)00003-4","journal-title":"Lancet Haematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel VL","year":"2012","unstructured":"Patel VL, Mah\u00e9vas M, Lee SY, et al.. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012, 119:5989-95. 10.1182\/blood-2011-11-393975","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima W","year":"2015","unstructured":"Ghanima W, Khelif A, Waage A, et al.. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015, 385:1653-61. 10.1016\/s0140-6736(14)61495-1","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13092157","article-title":"The use of rituximab in glomerulonephritis: what is the evidence?","volume":"13","author":"Zhu W","year":"2025","unstructured":"Zhu W, He H, Pai P. The use of rituximab in glomerulonephritis: what is the evidence?. Biomedicines. 2025, 13:10.3390\/biomedicines13092157","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466206-successful-treatment-with-rituximab-for-severe-immune-thrombocytopenic-purpura-during-hemodialysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:40:46Z","timestamp":1772527246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466206-successful-treatment-with-rituximab-for-severe-immune-thrombocytopenic-purpura-during-hemodialysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.104592","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}